Yahoo Web Search

Search results

    • Down 57%, Is AbCellera Biologics a Buy on the Dip?

      Down 57%, Is AbCellera Biologics a Buy on the Dip?

      Motley Fool via Yahoo Finance· 6 minutes ago

      KeyBanc has an overweight rating on the stock and a $7 per share price target, which implies a 103% gain over recent prices. Benchmark has a $9 per share...